Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AMM:DADI'
s FCF Margin % Range Over the Past 10 Years
Min: -13.21 Med: 1.69 Max: 14.99
Current: 14.99
During the past 13 years, the highest FCF Margin % of Dar Al Dawa Development and Investment was 14.99%. The lowest was -13.21%. And the median was 1.69%.
AMM:DADI's FCF Margin % is ranked better than 81.98% of 960
companies
in the Drug Manufacturers industry
Industry Median: 2.34
vs AMM:DADI: 14.99
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment FCF Margin % Chart
Dar Al Dawa Development and Investment Annual Data
AMM:DADI vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dar Al Dawa Development and Investment FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dar Al Dawa Development and Investment's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Dar Al Dawa Development and Investment's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment (AMM:DADI) has a FCF Margin % of 0.67% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Dar Al Dawa Development and Investment and its competitors. This is 60% below median its historical median of 1.69. According to the industry distribution chart, Dar Al Dawa Development and Investment ranks #173 out of 960 companies in the Drug Manufacturers industry, placing it in the top 18%.
Is Dar Al Dawa Development and Investment's FCF Margin % too high?
Dar Al Dawa Development and Investment's current FCF Margin % of 0.67% is 60% below median its 10-year median of 1.69. The Drug Manufacturers industry median FCF Margin % is 2.34. Dar Al Dawa Development and Investment's value of 0.67% is 71.4% below this industry median. Based on the distribution chart, Dar Al Dawa Development and Investment ranks #173 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dar Al Dawa Development and Investment ranks #173 out of 960 companies for FCF Margin %. This places Dar Al Dawa Development and Investment in the top 18% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.34. Dar Al Dawa Development and Investment's value of 0.67% is 71.4% below this benchmark. While the company's 10-year median is 1.69 vs. the industry median of 2.34, Dar Al Dawa Development and Investment has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.34, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dar Al Dawa Development and Investment's current FCF Margin % of 0.67% is 71.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Dar Al Dawa Development and Investment and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dar Al Dawa Development and Investment's current FCF Margin % is 0.67%, which is 60% below median its own 10-year median of 1.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD1.03, compared to a current price of JOD1.17 — trading 13.6% above its estimated fair value. The current FCF Margin % is 0.67%, which is 60% below median its 10-year median of 1.69 and 71.4% below the Drug Manufacturers industry median of 2.34. Dar Al Dawa Development and Investment's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current FCF Margin % is 0.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued.
The current stock price of JOD1.17 is trading 13.6% above its estimated GF Value™ of JOD1.03.
GuruFocus considers Dar Al Dawa Development and Investment to be Modestly Overvalued.
Key valuation signals for AMM:DADI:
FCF Margin %: 0.67% (60% below median its 10-year median of 1.69)
GF Value™: JOD1.03 vs. price of JOD1.17 (13.6% above fair value)
Industry Position: 71.4% below the Drug Manufacturers median (#173 of 960)
No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
77GF Score
Get the complete analysis for AMM:DADI
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:DADI has been successfully added to your 
